Dr Rosalind Glasspool

  • Honorary Clinical Senior Lecturer (Institute of Cancer Sciences)

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015
Number of items: 26.

2021

Spiliopoulou, P., Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Paterson, K., Zanivan, S. , Glasspool, R., Coffelt, S.B. and Zagnoni, M. (2021) Microfluidic technologies for immunotherapy studies on solid tumours. Lab on a Chip, 21(12), pp. 2306-2329. (doi: 10.1039/D0LC01305F) (PMID:34085677) (PMCID:PMC8204114)

2020

Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)

Lord, R., Rauniyar, J., Morris, T., Condon, O., Jones, R., Miller, R., Hall, M., Lofts, F., Glasspool, R. M. and Hudson, E. (2020) Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer, 30(7), pp. 1026-1033. (doi: 10.1136/ijgc-2019-000973) (PMID:32321768)

Concin, N., Ray-Coquard, I., Glasspool, R. M., Braicu, E., Farrelly, L., Votan, B., Mirza, M. R., Gonzalez Martin, A., Vergote, I. and Pignata, S. (2020) European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. International Journal of Gynecologic Cancer, 30(6), pp. 730-734. (doi: 10.1136/ijgc-2020-001464) (PMID:32404377)

Pfisterer, J. et al. (2020) Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, 21(5), pp. 699-709. (doi: 10.1016/S1470-2045(20)30142-X) (PMID:32305099)

Rees, M., Angioli, R., Coleman, R. L., Glasspool, R., Plotti, F., Simoncini, T. and Terranova, C. (2020) European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas, 134, pp. 56-61. (doi: 10.1016/j.maturitas.2020.01.005) (PMID:32059825)

Paoletti, X. et al. (2020) Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Network Open, 3(1), e1918939. (doi: 10.1001/jamanetworkopen.2019.18939) (PMID:31922558) (PMCID:PMC6991254)

2019

Clamp, A. R. et al. (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet (North American Edition), 394(10214), pp. 2084-2095. (doi: 10.1016/S0140-6736(19)32259-7) (PMID:31791688) (PMCID:PMC6902268)

Cohen, P. A. et al. (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 154(2), pp. 441-448. (doi: 10.1016/j.ygyno.2019.04.679) (PMID:31118141)

2018

Sassarini, J., Perera, M., Spowart, K., McAllister, K., Fraser, J., Glasspool, R., Harrand, R., Chitoni, M., Stallard, S. and Lumsden, M.-A. (2018) Managing vulvovaginal atrophy after breast cancer. Post Reproductive Health, 24(4), pp. 163-165. (doi: 10.1177/2053369118805344) (PMID:30348046)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

Kelemen, L. E. et al. (2018) rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences, 19(9), 2473. (doi: 10.3390/ijms19092473) (PMID:30134598) (PMCID:PMC6163881)

Dixon-Suen, S. C. et al. (2018) Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 118(8), pp. 1123-1129. (doi: 10.1038/s41416-018-0011-3) (PMID:29555990) (PMCID:PMC5931085)

2017

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi: 10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi: 10.1158/1055-9965.EPI-16-0631) (PMID:27677730) (PMCID:PMC5500198)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

2016

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi: 10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi: 10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Dixon, S. C. et al. (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), pp. 884-895. (doi: 10.1093/ije/dyw158) (PMID:27401727) (PMCID:PMC5644573)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

This list was generated on Sun Sep 19 06:00:35 2021 BST.
Jump to: Articles
Number of items: 26.

Articles

Spiliopoulou, P., Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Paterson, K., Zanivan, S. , Glasspool, R., Coffelt, S.B. and Zagnoni, M. (2021) Microfluidic technologies for immunotherapy studies on solid tumours. Lab on a Chip, 21(12), pp. 2306-2329. (doi: 10.1039/D0LC01305F) (PMID:34085677) (PMCID:PMC8204114)

Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)

Lord, R., Rauniyar, J., Morris, T., Condon, O., Jones, R., Miller, R., Hall, M., Lofts, F., Glasspool, R. M. and Hudson, E. (2020) Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer, 30(7), pp. 1026-1033. (doi: 10.1136/ijgc-2019-000973) (PMID:32321768)

Concin, N., Ray-Coquard, I., Glasspool, R. M., Braicu, E., Farrelly, L., Votan, B., Mirza, M. R., Gonzalez Martin, A., Vergote, I. and Pignata, S. (2020) European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. International Journal of Gynecologic Cancer, 30(6), pp. 730-734. (doi: 10.1136/ijgc-2020-001464) (PMID:32404377)

Pfisterer, J. et al. (2020) Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, 21(5), pp. 699-709. (doi: 10.1016/S1470-2045(20)30142-X) (PMID:32305099)

Rees, M., Angioli, R., Coleman, R. L., Glasspool, R., Plotti, F., Simoncini, T. and Terranova, C. (2020) European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas, 134, pp. 56-61. (doi: 10.1016/j.maturitas.2020.01.005) (PMID:32059825)

Paoletti, X. et al. (2020) Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer. JAMA Network Open, 3(1), e1918939. (doi: 10.1001/jamanetworkopen.2019.18939) (PMID:31922558) (PMCID:PMC6991254)

Clamp, A. R. et al. (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet (North American Edition), 394(10214), pp. 2084-2095. (doi: 10.1016/S0140-6736(19)32259-7) (PMID:31791688) (PMCID:PMC6902268)

Cohen, P. A. et al. (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 154(2), pp. 441-448. (doi: 10.1016/j.ygyno.2019.04.679) (PMID:31118141)

Sassarini, J., Perera, M., Spowart, K., McAllister, K., Fraser, J., Glasspool, R., Harrand, R., Chitoni, M., Stallard, S. and Lumsden, M.-A. (2018) Managing vulvovaginal atrophy after breast cancer. Post Reproductive Health, 24(4), pp. 163-165. (doi: 10.1177/2053369118805344) (PMID:30348046)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

Kelemen, L. E. et al. (2018) rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences, 19(9), 2473. (doi: 10.3390/ijms19092473) (PMID:30134598) (PMCID:PMC6163881)

Dixon-Suen, S. C. et al. (2018) Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 118(8), pp. 1123-1129. (doi: 10.1038/s41416-018-0011-3) (PMID:29555990) (PMCID:PMC5931085)

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi: 10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi: 10.1158/1055-9965.EPI-16-0631) (PMID:27677730) (PMCID:PMC5500198)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi: 10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi: 10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Dixon, S. C. et al. (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), pp. 884-895. (doi: 10.1093/ije/dyw158) (PMID:27401727) (PMCID:PMC5644573)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

This list was generated on Sun Sep 19 06:00:35 2021 BST.

Research datasets

Jump to: 2019
Number of items: 1.

2019

Ross, K., Keith, N. , Aitchison, I., Allbutt, E., Banks, E., Basra, S., Bilsland, A., Charalambous, A., Chapal, C., Drummond, M., Dunipace, S., Erridge, A., Fremin-Besombes, M., Glasspool, R., Hamilton, V., Hanna, C. , Herfurth, L., Humpleby, M., Hush, G., Ivanova, Y., Jones, R. , Kaleta-Pyrek, A., Kalt, L., Kantor, M., Karolak, G., Keith, A., Klink, S., Laing, B., Lister, A., Mallon, E., Mccann, E., McLaughlin, R., Merchant, Z., Mozel, A., Mrozek, O., Painter, C., Paul, J. , Paxton, J., Perry, M. , Prendergast, E., Proudfoot, B., Raina, T., Roberts, F., Safrany, S., Scott, J., Sleight, R., Smith, C., Strain, E., Stricevic, M., Svanera, S., Tobias, E. , Vansteenhouse, H., Williams, N. and Zhang, H. (2019) A collaborative approach to exploring the future of Cancer treatment and care in relation to Precision Medicine: A design perspective. [Data Collection]

This list was generated on Sun Sep 19 06:01:06 2021 BST.